MaxCyte IPO Presentation Deck

MaxCyte: Leading Partner for Complex Cellular Engineering 50+ Potential SPLs Current addressable market CRISPR July 2021 Allogene 13 SPLS signed since 2017 13 strategic Platform Licenses (SPLs), including 2 signed in 2021- editas APEIRON BIOLOGICS Kite GREAD Beam KSQ® 75+ Programs Clinical Licenses that are part of our SPLs CONFIDENTIAL CARIBOU BIOSCIENCES MYELCID CASEBIA THERAPEUTICS >15% are in the clinic* PRECISION BIOSCIENCES "IND or later CO celularity VOR BIOPHARMA

View entire presentation